WO1995013288A1 - Surface membrane proteins and their effect on immune response - Google Patents

Surface membrane proteins and their effect on immune response Download PDF

Info

Publication number
WO1995013288A1
WO1995013288A1 PCT/US1994/012985 US9412985W WO9513288A1 WO 1995013288 A1 WO1995013288 A1 WO 1995013288A1 US 9412985 W US9412985 W US 9412985W WO 9513288 A1 WO9513288 A1 WO 9513288A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
cells
protein
binding
hla
Prior art date
Application number
PCT/US1994/012985
Other languages
English (en)
French (fr)
Inventor
Carol Clayberger
Alan M. Krensky
Original Assignee
The Board Of Trustees For The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees For The Leland Stanford Junior University filed Critical The Board Of Trustees For The Leland Stanford Junior University
Priority to AU10939/95A priority Critical patent/AU1093995A/en
Priority to EP95901851A priority patent/EP0730604A4/en
Priority to JP7514017A priority patent/JPH09508617A/ja
Publication of WO1995013288A1 publication Critical patent/WO1995013288A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
PCT/US1994/012985 1993-11-10 1994-11-10 Surface membrane proteins and their effect on immune response WO1995013288A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU10939/95A AU1093995A (en) 1993-11-10 1994-11-10 Surface membrane proteins and their effect on immune response
EP95901851A EP0730604A4 (en) 1993-11-10 1994-11-10 SURFACE MEMBRANE PROTEINS AND THEIR EFFECT ON THE IMMUNE RESPONSE
JP7514017A JPH09508617A (ja) 1993-11-10 1994-11-10 表面膜タンパク質および免疫応答に対するそれらの影響

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15049393A 1993-11-10 1993-11-10
US08/150,493 1993-11-10

Publications (1)

Publication Number Publication Date
WO1995013288A1 true WO1995013288A1 (en) 1995-05-18

Family

ID=22534794

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012985 WO1995013288A1 (en) 1993-11-10 1994-11-10 Surface membrane proteins and their effect on immune response

Country Status (5)

Country Link
EP (1) EP0730604A4 (ja)
JP (1) JPH09508617A (ja)
AU (1) AU1093995A (ja)
CA (1) CA2176208A1 (ja)
WO (1) WO1995013288A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046633A1 (en) * 1997-04-11 1998-10-22 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
EP0939643A1 (en) * 1996-05-22 1999-09-08 The Board Of Trustees Of The Leland Stanford Junior University Immunomodulating compounds comprising d-isomers of amino acids
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
JP2001504451A (ja) * 1996-09-18 2001-04-03 ヴィルドナー，ゲルヒルト 自己免疫疾患の診断薬と治療薬となるペプチド類
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US7011834B1 (en) * 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US7094413B2 (en) 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, Vol. 87, No. 2, issued January 1991, HAIRE et al., "Mitogen-Induced Preferential Synthesis of Proteins During the G0 to S Phase Transition in Human Lymphocytes", see page 182, col. 2, the abstract no. 14222; & EXPERIMENTAL CELL RESEARCH, 1988, 179(1), 65-78. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Vol. 91, issued March 1994, CIAVARRA et al., "Heat Stress Induces hcs70/Nuclear Topoisomerase I Complex Formation In Vivo: Evidence for hcs70-Mediated ATP-Independent Reactivation In Vitro", pages 1751-1755. *
See also references of EP0730604A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011834B1 (en) * 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
EP0939643A1 (en) * 1996-05-22 1999-09-08 The Board Of Trustees Of The Leland Stanford Junior University Immunomodulating compounds comprising d-isomers of amino acids
EP0939643A4 (en) * 1996-05-22 2003-04-16 Univ Leland Stanford Junior IMMUNOMODULATORY COMPOUNDS COMPRISING D ISOMERS OF AMINO ACIDS
JP2001504451A (ja) * 1996-09-18 2001-04-03 ヴィルドナー，ゲルヒルト 自己免疫疾患の診断薬と治療薬となるペプチド類
WO1998046633A1 (en) * 1997-04-11 1998-10-22 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US7267822B2 (en) 1997-04-11 2007-09-11 Genzyme Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
US7094413B2 (en) 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents

Also Published As

Publication number Publication date
EP0730604A4 (en) 1998-01-07
EP0730604A1 (en) 1996-09-11
CA2176208A1 (en) 1995-05-18
JPH09508617A (ja) 1997-09-02
AU1093995A (en) 1995-05-29

Similar Documents

Publication Publication Date Title
Thomas The leukocyte common antigen family
Clevers et al. The T cell receptor/CD3 complex: a dynamic protein ensemble
Kaye et al. Selective development of CD4+ T cells in transgenic mice expressing a class II MHC-restricted antigen receptor
JP4170389B2 (ja) 蛋白質チロシンキナーゼキメラによる細胞性免疫の再指示
US20060171954A1 (en) Antigen specific activated T-lymphocytes, detection and use
US5888512A (en) Lymphocyte activity regulation by HLA peptides
JP3025271B2 (ja) 無細胞ｔ細胞抗原レセプターおよびその臨床的利用
Ostrov et al. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues.
MX2012006199A (es) Agentes para tratamiento de enfermedad.
Davidson et al. Distribution and immunoregulatory properties of antisecretory factor
WO1995013288A1 (en) Surface membrane proteins and their effect on immune response
WO1995026979A1 (en) Cytotoxic t-cell lymphocyte ('ctl') activity regulation by class i mhc peptides
HU224137B1 (hu) Kiméra-receptorokat kódoló DNS-molekulák, a DNS-molekulákat hordozó vektorok és a DNS-molekulákat expresszáló sejtek
Devaux et al. Generation of monoclonal antibodies against soluble human T cell receptor polypeptides
Osborn et al. Amino acid residues required for binding of lymphocyte function-associated antigen 3 (CD58) to its counter-receptor CD2.
CA2220098A1 (en) Cd6 ligand
EP0579747A4 (en) Method of modulating mammalian t-cell response
AU697246B2 (en) Method for identifying individuals suffering from a cellular abnormality
JPH10511985A (ja) ヒトグルタミン酸デカルボキシラーゼ（ｇａｄ）からの自己反応性ペプチド
EP0920502A1 (en) Methods and means for modifying complement activation
Hayball et al. The immune function of MHC class II molecules mutated in the putative superdimer interface
KR0167016B1 (ko) 항원 특이적인 활성화된 t 림프구, 이것의 검출 및 사용방법
GAMMA-DElTA et al. DISTINCT MOlECULAR FORMS OF HUMAN
Straus Heterogeneity of function in human CD4-8-T-cell clones from the periphery
Lybarger et al. Biochemical Features of the MHC-Related

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2176208

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995901851

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995901851

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995901851

Country of ref document: EP